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ABSTRACT
Shortages of injectable drugs affect many cancer patients and
providers in the U.S. today. Scholars and policymakers have
recently begun to devote increased attention to these issues,
butonlya fewtangible resourcesexist toguideclinicaloncologists
in developing strategies for dealing with drug shortages on a
recurring basis.This article discusses existing information from
the scholarly literature, policy analyses, and other relevant
sources and seeks to provide practical ethical guidance to the
broad audience of oncology professionals who are increasingly
confronted with such cases in their practice. We begin by
providing a brief overviewof the history, causes, and regulatory
context of oncology drug shortages in the U.S., followed by a
discussion of ethical frameworks that have been proposed in
this setting.Weconcludewithpractical recommendations for
ethical professional behavior in these increasingly common
and challenging situations. The Oncologist 2014;19:186–192
Implications for Practice: Shortages of injectable drugs affect many cancer patients and providers in the U.S. today.When a drug
shortage occurs, oncologists face an acute moral dilemma: how to fairly manage or ration care in a situation of scarcity.
Unfortunately, oncologists typically receive littleorno training regarding theappropriateethical frameworksandconsiderations in
such circumstances.Therefore, this article seeks toprovide anoverviewofexisting information fromthe scholarly literature, policy
analyses, andother relevant sources, inorder toprovidepractical ethical guidance to thebroadaudienceofoncologyprofessionals
who are increasingly confronted with such cases in their practice.
Consider the following cases:
J.W. is an 8-year-old girl diagnosed with acute lym-
phoblastic leukemia with intermediate risk features and
an overall favorable prognosis. She receives induction
therapywithvincristine, corticosteroids,andL-asparaginase
and attains a complete remission. During consolidation
therapy that includes systemic chemotherapy and in-
tensive intrathecal therapy for central nervous system
prophylaxis, her physicians are informed that there is
a critical shortage of preservative-freemethotrexate that
is necessary for the administration of both the high-dose
systemic methotrexate infusions and the intrathecal
doses of methotrexate that are scheduled during her
consolidation therapy.
A.L. is a 55-year-old woman diagnosed with stage III
ovarian cancer. She receives debulking surgery and
undergoes chemotherapy with paclitaxel and carbo-
platin. Within 4 months of her last cycle of paclitaxel
and carboplatin, she develops recurrent disease. Her
physicians start monthly therapy with pegylated lipo-
somal doxorubicin. After two cycles of therapy, she
has shrinkage of her disease. However, her physicians
are informed that there is a critical shortage of liposo-
mal doxorubicin and that alternative plans should be
considered.
Should these patients’ physicians change regimens, lower
doses, wait until the supply returns, or hold off starting chemo-
therapy on a different patient to give these patients access?
What features of each case are relevant and appropriate to
consider when weighing each of these patients’ needs against
those of others? How can an oncologist best determine what
behavior in these circumstances is most consistent with ethical
principles?
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INTRODUCTION
These cases demonstrate just two of the diverse situations in
which oncology drug shortages can affect cancer patients
today, which include shortages of drugs prescribed with
curative intent, palliative treatment options, and essential
supportive care medications. As a result of these shortages,
difficult decisions have to be made, and care for cancer
patientsmaysuffersignificantly. Shortagesmay force rationing
of care or in some cases alternative drugs must be prescribed,
which may be less efficacious, more toxic, and/or more
expensive. For example, the recent shortage of mechloreth-
amine forced oncologists to substitute cyclophosphamide for
treatment of pediatric Hodgkin’s lymphoma, and a retrospec-
tive comparison of these two regimens, while limited by small
numbers of patients, revealed that the substitution was
significantly less effective [1] and resulted in higher rates of
disease recurrence.
Scholars and policymakers have recently devoted increased
attention to these issues, but opinions continue to diverge about
how oncology practices and providers should act when faced
with these difficult circumstances at the bedside. Although this
highly charged topic is becoming a familiar issue, only a few
resources exist to guide strategy in dealing with drug shortages
on a recurring basis [2]. This article discusses the existing sch-
olarly work regarding these issues, as well as information from
policy analyses and other sources, in order to provide practical
and ethical guidance to the broad audience of oncology
professionals who are increasingly confronted with such cases
in their practice. In this article, we begin by providing a brief
overview of the history, causes, and regulatory context of onco-
logy drug shortages in the U.S., followed by a discussion of
ethical frameworks that are available for decision making in this
setting.We conclude with practical recommendations for onco-
logists in these increasingly common and challenging situations.
THE HISTORY, CAUSES, AND REGULATORY CONTEXT OF
ONCOLOGY DRUG SHORTAGES IN THE UNITED STATES
Drug shortages are not a new problem in U.S. oncology
practice. Concerns about scarcity of paclitaxel date to its first
demonstration of value in ovarian cancer in the late 1980s
when the sole source of production was from the bark of the
Pacific Yew tree [3]. Of note, there has been no shortage of
taxol since itwasapprovedbecause taxol is nowmadeby semi-
synthesis. Concerns about wider drug shortages in oncology
are evidenced by a stakeholders’ meeting on drug shortages
convened more than a decade ago by the American Medical
Association and the American Society of Health-System
Pharmacists (ASHP) after increasing member contacts about
concerns in this area [4].Mechanismsunderlyingshortagesare
complex, with no single cause, but were found to include
material shortages, recalls, businessdecisions, andstockpiling,
along with limitations on communication between manufac-
turers related to antitrust concerns.
Although drug shortage problems have existed for many
years, as Michael Link, former president of the American
Society of Clinical Oncology, succinctly noted, “We have had
shortages before, but they have been intermittent, and never
anything as extensive both in terms of the breadth of drugs
affected and the depths of shortages and how long they lasted”
[5]. Current data regarding drug shortages can be found on
the website http://www.fda.gov/Drugs/drugsafety/DrugShor-
tages/default.htm. Indeed, the Food and Drug Administration
(FDA) reported 178 drug shortages in 2010, with 74% of
shortages involving sterile injectable drugs, including chemo-
therapy [6]. In 2011, there were 251 drug shortages reported
to the FDA, 183 involving sterile injectable drugs [6]. Of
note, the FDA’s definition of drug shortage considers only
medically necessary drugs for which there is no other source
or alternative. The broader definition proposed by the ASHP
includes all instances in which “a supply issue affects how the
pharmacy prepares or dispenses a drug product or influences
patient care when prescribers must use an alternative agent.”
Thus, the ASHP definition leads to the identification of even
more shortages [7, 8]. A recent ASHP study found that nearly
all hospitals surveyed had experienced at least one drug
shortage in 2010, and most had experienced many shortages
[9]. A more recent ASHP survey found that oncology drug
shortages led to delays in chemotherapy, complicated the
conduct of clinical research, increased the risks of medication
errors, and were perceived to have had numerous other
concerning downstream effects [10].
Fundamentally, the economic underpinnings of shortages
in themarket formedically necessary prescription drugs relate
to a phenomenon economists dub the “price inelasticity” of
both demand and supply [11]. In brief, demand is relatively
unresponsive to changes in price becausemedically necessary
drugshave fewsubstitutesandbecausedrugcostsare typically
covered by insurance. Supply is slow to respond to price, given
the complexity of the drug production process and regulatory
environment, which limit the ability for industry to increase
capacity quickly. Analysts observe that there is little incentive
for suppliers to carry reserve inventory, given limited shelf life
and because oversupplied drugs cannot be marketed even at
a very low price if there is insufficient demand [4]. Moreover,
some have argued that price itself is fixed to some extent by
Medicare payment policies that limit reimbursement for
injectable generics to 6% over the average sales price and
calculate the average sales price in a way that leads to a two-
quarter lag in price updating and, therefore, a reduced price
responsiveness to changed demand [12, 13]. For these
reasons, shortages in oncology drugs may be more easily
precipitated by unexpected or rapid changes in supply or
demand compared with other commercial goods.
Demand is relatively unresponsive to changes in price
because medically necessary drugs have few sub-
stitutes and because drug costs are typically covered
by insurance. Supply is slow to respond to price, given
the complexity of the drug production process and
regulatory environment, which limit the ability for
industry to increase capacity quickly.
The market for injectable oncology drugs is particularly
complex.Onthesupplyside,genericdrugscurrentlyconstitute
at least half the market, and that proportion is growing and
will continue to grow as more drugs emerge from patent
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protections [12]. Individual generic oncology drugs are usually
supplied by three or fewer manufacturers, and these manu-
facturers have limited facilities and lines on which cytotoxic
drugs may be produced, limiting the ability to substitute
production in the situation of a shortage [12]. A recurrent
problemexistswith regard tomanufacturing capacity, caused
by aging facilities, lack of redundancy of facilities, and ulti-
mately the low-profit margin, which makes it impractical
to devote industry resources to the construction of new
facilities. In contrast, Europe, which lacks the rigid price
control system on generics, has had no serious shortage
problem. The Department of Health and Human Services
reported in 2006–2010 an increase in both the overall
quantity and range of drugs produced by generic oncology
drug manufacturers (partly related to the timing of patent
expirations) in the face of stable manufacturing capacity [6].
Given the increase in capacity utilization observed during
that time period, it is not surprising to find shortages in drugs
for which volume and prices had been declining, as manufac-
turers strategically diverted their resources toward growing
sourcesofrevenue.Regulatorybarrierstoentryofnewsuppliers
further complicate the situation. Of note, shortages may vary
fromone hospital system to the next, depending on their ability
to stockpile drug and to find black market sources.
Recently, legislators and government administrators have
taken a number of steps to respond to these issues. In October
2011, along with the release of the Department of Health and
HumanServicesanalysis, PresidentObama issuedanExecutive
Order that broadened reporting requirements regarding
manufacturing discontinuances, ordered the FDA to expedite
certain regulatory reviews, and required communication with
the Department of Justice about collusion or price gouging
related to shortages [14]. In February 2012, to address the
shortage of liposomal doxorubicin, the FDA approved tempo-
rary importation of an FDA-unapproved replacement brand of
thedrug fromforeignsources [15], recentlyapprovedageneric
doxorubicin under expedited review [16], and also worked to
maintain supplies of preservative-free methotrexate. In July
2012, President Obama signed bipartisan legislation that
included provisions requiring manufacturers to notify the
FDA 6months before an anticipated shortage and instituting
a generic drug user fee to provide resources for expedited
review of generic drug applications [17].
Nevertheless, changes in the political and regulatory
context have not successfully addressed the root causes of
drug shortages, meaning providers will continue to be faced
with shortages of critical chemotherapies and essential
supportive care medicines. Therefore, ethical considerations
regarding allocation of scarce resources—and the need for
practical recommendations for dealing with oncology drug
shortages—remain salient issues for clinical oncologists.
ETHICAL FRAMEWORKS
Ultimately,when anoncologydrug shortageoccurs and supply
cannot be quickly increased tomeet demand, oncologists face
an acutemoral dilemma: how to fairlymanageor ration care in
a situation of scarcity. Unfortunately, oncologists in the U.S.
typically receive little or no training regarding the appropriate
ethical frameworks and considerations in such circumstances.
Moreover, because the U.S. health care system has generally
relied on implicitmechanisms of resource allocation, based on
insurancestatusorability topay, oncologists typicallyhavehad
little direct experience with explicit prioritization. Therefore,
oncologistsmust develop an understanding of the ethical frame-
works that may help guide behavior in such circumstances.
Scholars have drawn fromcenturies of relevant philosoph-
ical deliberation to propose general frameworks for rationing
health care interventions [18–21]. Of note, important lessons
may be gleaned from experiences with explicit prioritization
and rationing that have occurred in certain specific situations
in the U.S., including allocation of organ transplants, hemo-
dialysis, and proton therapy [22–26]. Just as in the case ofdrug
shortages, these situationshavebeenones inwhichAmericans
have had to confront the uncomfortable reality that it is not
possible to provide a health care intervention to all whomight
benefit—situations that have been described by Calabresi and
Bobbitt as “tragic choices” [27].
Ingeneral, utilitarian frameworks for rationingprioritizeon
the basis of a principle of maximizing welfare at the societal
level, often relying on cost-effectiveness analysis for guidance.
However, such approaches conflict with the respect for indi-
vidual human dignity that permeates the American political
culture and consciousness. Therefore, scholars have sought
alternative frameworks and have been particularly careful to
avoid comparisons of theworthiness ofdifferent individuals to
receive scarce health care resources. Moreover, a utilitarian
approachmay have appeal at the level of setting public health
policy, but it is difficult to apply at the level of the individual
clinical encounter in which oncologists are expected to have
a professional fiduciary responsibility for each patient. How
doctors can fulfill their dual obligations to individual patients
and society is problematic in a number of settings [28, 29].This
well-described dilemma is magnified when an oncologist is
forced to choose between the needs of an individual patient in
clinic versus others in their practice or community in cases of
oncology drug shortages. Importantly, these decisions should
not be made on a case-by-case basis and not in isolation.
In general, utilitarian frameworks for rationing
prioritize on the basis of a principle of maximizing
welfare at the societal level, often relying on cost-
effectiveness analysis for guidance. However, such
approaches conflict with the respect for individual
human dignity that permeates the American political
culture and consciousness.
Recently, specific frameworks have been proposed for
approaching situations of unanticipated shortages of medi-
callynecessarydrugssuchasthosedescribedintheintroductory
cases. Valgus and colleagues [2] endorse the “accountability
for reasonableness” framework, initially described by Daniels
and Sabin [30], for application to the context of oncology drug
shortages specifically. Rosoff has provided more detailed
specification and adaptation of this framework for guiding the
equitable short-termrationingofdrugs in short supply [31,32].
This framework emphasizes a transparent process, consis-
tently enforced, and relevant rules based on objective criteria;
a mechanism for individual appeal and for revision of the
©AlphaMed Press 2014
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allocation system over time; and consideration of fairness,
particularly noting the importance of preventing powerful
individuals or patients of influential providers from receiving
preferential treatment. Rosoff focuses on large hospitals and
envisions formation of a standing drug shortage allocation
committee that includes a patient representative, along with
other relevant hospital stakeholders. Based on these un-
derlying principles, he proposes several specific steps for
adoption when a drug shortage arises. The first involves using
substitute therapies of comparable equivalence whenever
possible. The second involves setting priorities for remaining
cases in which the drug might be used, with the foremost
criterion for allocation being the expected clinical benefit.
Rosoffgenerally favors continuationof therapy forapatienton
a drug over allocation to a patient newly starting a drug and
advocates consideration of a shorter duration of therapy or
lower doses to conserve the drug whenever this is clinically
reasonable. In the settingofoncology treatment, however, this
approach is unlikely to prove clinically reasonable very often,
particularly for curative regimens, and is unappealing unless
clinical trials have demonstrated equivalent activity with
shorter courses or lower doses. Of note, Rosoff specifically
articulates certain criteria that should not be considered in the
allocation process: ability to pay, ethnicity or citizenship, age
(unless directly related to the specific drug’s efficacy), or any
notion of social worth.
Several scholars have provided comments critiquing or
building on Rosoff’s proposal. Burda notes that for the
allocation process to be truly fair, attention is necessary to
decrease the influenceofbiases and conflicts of interest on the
part of allocation committee members [33]. This includes
recusalofcommitteememberswhohaveeithercurrentorpast
personal or professional relationships with patients being
evaluated for receipt of a scarce drug, as well as removal of
identifying information (including characteristics that ought
not be considered in the allocation process, such as sex, race,
age, marital and parental status, and other sociodemographic
characteristics). She also emphasizes the importance of
managing the emotional and psychological impact of these
classic “tragic choices”on caregivers and allocation committee
members, as well as patients. Goodman also emphasizes the
need to consider themanagement ofdistress amongproviders
confronted with this difficult situation [34]. Bamford and
colleagues argue that clinical rather than cost effectiveness be
clearly identified as the criterion onwhich allocation decisions
should be based [35].They also suggest greater clarification of
the roles of need and efficacy in guiding allocation decisions.
Finally, they note that greater clarification of the appropriate
role of physicians in the allocation process is necessary.
Several other groups have articulated relatively similar
frameworks for allocation of resources in other more specific
circumstances of drug shortages [36, 37]. In the setting of
a potential widespread shortage of injectable generics in
Canada, a group of Ontario ethicists endorsed similar fair
process principles, while highlighting six overarching ethical
principles: beneficence (doing good), solidarity, utility, equity,
stewardship, and trust [38]. They further specified those
principles with a three-stage approach suitable for their
cultural and regulatory environment. The first stage involves
strategies to preserve the standard of care such as minimizing
waste, substituting drugs of equivalent efficacy, and pursuing
alternative sources. The second and third stages involve the
application of primary allocation principles to optimize
therapeutic benefit and secondary allocation principles that
ensure fair access.
Peppercorn and colleagues provide more concrete guid-
ance that is of specific relevance to oncologists in these
circumstances.Theydiscuss indetailone institution’sapproach
to rationing a promising novel oncology therapy in scarce
supply [39]. After considering the classic principles of respect
for patient autonomy, beneficence (and its corollary of
nonmalfeasance), and justice, these scholars conclude that
“objective medical criteria should guide our attempts to meet
these sometimes competing ethical obligations.” They sepa-
rate thesemedical criteria into twocomponents:medical need
(the risk of harm in the absence of the intervention—which
depends on both prognosis and availability of alternative
therapies) and chanceof benefit (which incorporatesevidence
on the safety and efficacy of the intervention itself, the
patient’s life expectancy from both the disease and any
comorbid conditions, and the patient’s likelihood of receiving
an adequate course of treatment, which in turn depends on
both comorbidities and adherence). Of note, this group
reported thatwhile they chose to avoid consideration of social
criteria, such as prior trial participation, they did consider
likelihood of treatment compliance, including concerns about
ability to keep appointments or other logistical concerns,
which may in turn reflect disability or lack of social privilege in
a way that may not be ideal. Beyond establishment of medical
criteria, Peppercorn and colleagues recommended allocation
on a first-come/first-served basis as most ethically appropri-
ate, without subsequent consideration of other sociodemo-
graphic factors. Overall, the system articulated by this group
provides clear guidelines that are specifically applicable to
oncologyshortages.However, justaswithRosoff’sanalysis, the
generalizability of this approachmaybe limited in settings that
are substantially different from the large academic medical
center in which it was developed.
Of note, the frameworks discussed share many common-
alities, includinganemphasisoncertainkeyprinciples, including
beneficenceandequity,aswellasarecognitionofthe importance
of establishing a fair, accountable, and transparent process.
However, certain contrasts merit note. Specifically, as noted
above, in thecircumstancesof thedrugshortageofsipuleucel-T,
Peppercorn and colleagues developedwaiting lists with priority
basedon a first-come/first-served approach; they recognized
the potential limitations of this approach and required that
physicians act to minimize potential differences in patient
awareness or ability to access the system [39]. Given concerns
that such an approach might nevertheless favor more well-
informed, privilegedmembers of society, Rosoff and colleagues
have instead proposed a coin toss for a decision between two
clinically equivalent patients [32]. Gibson notes that either of
theseapproaches constitutes reasonable secondary allocation
principles that can be developed and sanctioned by affected
stakeholders [38]. Ultimately, despite these differences re-
garding the potential operationalization of secondary alloca-
tion principles to follow consideration of clinical benefit, all of
these scholars agree that the process should take care not to
disadvantage those from underprivileged groups. `
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CONCLUSION AND RECOMMENDATIONS FOR THE
CLINICAL ONCOLOGIST
Drug shortages like those presented in the introductory cases
are likely to recur and pose difficult challenges for the
practicingoncologist. Shortagesofdrugs forwhichalternatives
maybe substituted canbe addressed in a relatively straightfor-
ward fashion. Unfortunately, although existing regulations
may provide greater advance notice and opportunity for
planning, shortages of oncology drugs are likely to continue to
occur and to persist for unpredictable durations. Existing
guidelines focusprimarilyonthe roleofpharmacists [8]and fail
to provide clear guidance for practical decision making for the
practicing oncologist.Therefore, after careful consideration of
the existing literature on oncology drug shortages, we make
several recommendations to the practicing oncologist facing
a drug shortage, as summarized in Table 1.
First, because some drug shortages may occur without
adequate warning even if new reporting mechanisms are
successful, it is important for oncologists in institutional
settings to participate in the development of standing insti-
tutional allocation committees, even when no active shortage
exists. Where an ethics committee or other similar structure
alreadyexistswithinan institution,a subcommitteeorworking
group of members from these existing committees may be
arranged todevelopprocedures and tobe called on should the
need arise. Such committees are an excellent mechanism by
which to ensure legitimacy of the allocation process and
adherencetokeyethicalprinciples, includingtransparencyand
fairness. Ideally, as consistently supported by the scholarly
literature reviewed above, such committees would include
diverse representatives of the medical and allied professions
(including bioethicists where available), administrators, and
the patient population and public whom they serve. By cre-
ating an infrastructure and process for allocation decisions in
advance of any particular shortage situation, oncologists can
avoid the ethically challenging situation of bedside rationing
that they otherwise may confront during a shortage. Commit-
teesmightconsidercriteria suchasclinical benefitasdescribed
Table 1. Practical Recommendations for Preventing and Managing Oncology Drug Shortages
What Can the Practicing Oncologist Do?
1. Organize and Plan
Providers can prepare for shortages by forming standing allocation committeeswherepracticable (e.g., institutional settings), evenwhen
no active shortage exists. Oncologists in individual practices forwhich standing committees are impracticalmight establish a deliberation
group to share strategies and develop standard operating procedures in anticipation of the eventual occurrence of a shortage.
Affords ability to assemble a multidisciplinary group of informed stakeholders, including physicians (academic and community),
pharmacists, nurses, patients, and public representatives tomake decisions, reviewdecisions, and iteratively improve the congruence
of the process with the community’s values and vision
Allows adherence to key ethical principles, including transparency and fairness
Forges relationships between physicians and other care providers, including pharmacists, to facilitate appropriate action when
a shortage develops
2. Train and Educate
Oncologists should seek to improve theirownknowledgeof bioethics, aswell as thatof their peers and trainees, particularly regarding the
ethical frameworks for health care rationing decisions.
Provides knowledge necessary to appreciate rationale underlying different approaches toward resource allocation and time to reflect
on ethical principles in a less pressured environment than an actual drug shortage
Might include development and use of effective educational techniques such as standardized patient simulation and group case
discussions
3. Research
Oncologists must be active leaders in conducting research that gathers information of key importance to decision makers in this setting.
Identifies public values and preferences relevant to decision making
Strengthens the evidence base on which to ground decisions regarding the clinical benefit of different treatment approaches
4. Communicate
Oncologistsmustdevelop thecommunicationskillsnecessary tomaintain trustandengagethebroadercommunity in thesechallenging
circumstances.
Focuses on the development of effective communication strategies to engage internal/external stakeholders around priority-setting
goals, criteria, processes, and decisions
5. Recognize and Manage Distress
Oncologists should recognize thedistress that is common in these circumstancesandengage colleagues inpsychosocial caredisciplines
to help meet the unique needs of both the patient and professional communities.
Promotes the importance of adequately appreciating and addressing the psychological consequences of a drug shortage and its
management
6. Advocate
Oncologists shoulduse their experience to advocate foreconomic, policy, and legislative reforms topreventoncologydrug shortages in
the future.
Supports interventions that address root causes of drug shortages
Can draw on the expertise of professional societies that can provide relevant information and advocacy opportunities to members
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above to avoid first-come/first-served and informal rationing
by individual providers.
Of note, differences in practice environments may lead to
substantial differences in what resources and needs exist,
influencing the approach to decision making in different
settings. Physicians practicing outside the context of the large-
hospital scenario given detailed attention by bioethicists to
datemust consider how best to develop a participatorymodel
of allocation within their own environments. Specifically,
smaller providers are encouraged to communicate and share
strategies for incorporating ethical deliberation in anticipation
of the eventual occurrence of a shortage. Instead of a formal
committee, providers might establish a deliberation group,
which may or may not include all of the participants than an
analogous institutional committee would. The prior develop-
ment of standard operating procedures for these foreseeable
circumstances may be beneficial for addressing the potential
communication and other challenges to arriving at and imple-
menting ethically sound decisions.
Second, oncologists should educate themselves and their
colleagues in the aspects of bioethics likely to be relevant
to their practice, including the ethical frameworks that have
been developed to guide health care rationing decisions. In
particular, consideration should be given to understanding the
arguments, both theoretically based and empirically derived
from studies of public opinion, that generally weigh against
consideration of certain personal characteristics in allocation
decisions. In the setting of a shortage, it may become difficult
for providers to avoidemotional or inappropriate considerations
unless they have previously received training to appreciate the
rationale against doing so.
Third, oncologists should contribute to research to better
understandpublic values andpreferences regarding allocation
deliberation and outcomes, which may help to guide the
specific considerations and procedures adopted by allocation
committees. Also important is continued pursuit of more tra-
ditional forms of clinical research and comparative effective-
ness research to better define therapeutic benefits of specific
drugs in a variety of clinical circumstances.
Fourth, oncologists should collaborate with experts in
communication to identify the best approaches for maintain-
ing trust and engaging internal/external stakeholders around
priority-setting goals, criteria, processes, anddecisions.Oncol-
ogists must develop the skills to communicate effectively in
these difficult circumstances. Programming should be tailored
to meet the needs of practicing oncologists in a variety of
settings, from those in private practice to those in large
institutions.
Fifth, allocation decisions are classic “tragic choices” that
may result in substantial psychological distress not only for
patients but also for providers and those charged with
allocation decisions. Oncologists should recognize and seek
help inmanaging this distress, includingharnessing supportive
care services for both patients and providers. These prepara-
tions may help providers manage the complex emotional
issues that are likely to arise in the inevitable instance that
there is not enough of a drug for all of their patientswhomight
benefit.
Finally, beyond clinicians’ duties to individual patients, the
practicing oncologist has a duty to advocate for systemic
changes thatwould effectively address the root causes of drug
shortages. Some believe that fundamental changes to the
regulatory environment and to the drug reimbursement
system are necessary. For example, it may be prudent to
establish a pricing floor for generic chemotherapy drugs
[40]. Intervention may also be appropriate to decrease the
regulatory burden on potential new suppliers, while ensuring
thatpatient safety is notaffected. Finally, the FDAmust receive
adequate support to clear its backlog of unapproved generic
applications and decrease the timeline to approval of generic
drugs, as it recently did in approving generic doxorubicin, in
order to allow suppliers to enter the market when shortage is
anticipated [40]. Suchpolicy changes are critically necessary to
decrease the number of situations in which the difficult
processes of resource allocation discussed above must be
applied.
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